Suppr超能文献

不同疫情波次中肾移植受者严重新型冠状病毒肺炎的预测因素:西班牙登记处分析

Predictors of severe COVID-19 in kidney transplant recipients in the different epidemic waves: Analysis of the Spanish Registry.

作者信息

Villanego Florentino, Mazuecos Auxiliadora, Pérez-Flores Isabel M, Moreso Francesc, Andrés Amado, Jiménez-Martín Carlos, Molina María, Canal Cristina, Sánchez-Cámara Luis A, Zárraga Sofía, Ruiz-Fuentes María Del Carmen, Aladrén María José, Melilli Edoardo, López Verónica, Sánchez-Álvarez Emilio, Crespo Marta, Pascual Julio

机构信息

Department of Nephrology, Hospital Universitario Puerta del Mar, Cádiz, Spain.

Department of Nephrology, Hospital Clínico San Carlos, Madrid, Spain.

出版信息

Am J Transplant. 2021 Jul;21(7):2573-2582. doi: 10.1111/ajt.16579. Epub 2021 Apr 12.

Abstract

SARS-CoV-2 infection has produced high mortality in kidney transplant (KT) recipients, especially in the elderly. Until December 2020, 1011 KT with COVID-19 have been prospectively included in the Spanish Registry and followed until recovery or death. In multivariable analysis, age, pneumonia, and KT performed ≤6 months before COVID-19 were predictors of death, whereas gastrointestinal symptoms were protective. Survival analysis showed significant increasing mortality risk in four subgroups according to recipient age and time after KT (age <65 years and posttransplant time >6 months, age <65 and time ≤6, age ≥65 and time >6 and age ≥65 and time ≤6): mortality rates were, respectively, 11.3%, 24.5%, 35.4%, and 54.5% (p < .001). Patients were significantly younger, presented less pneumonia, and received less frequently specific anti-COVID-19 treatment in the second wave (July-December) than in the first one (March-June). Overall mortality was lower in the second wave (15.1 vs. 27.4%, p < .001) but similar in critical patients (66.7% vs. 58.1%, p = .29). The interaction between age and time post-KT should be considered when selecting recipients for transplantation in the COVID-19 pandemic. Advanced age and a recent KT should foster strict protective measures, including vaccination.

摘要

严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染在肾移植(KT)受者中导致了高死亡率,尤其是在老年受者中。截至2020年12月,西班牙登记处已前瞻性纳入1011例感染新型冠状病毒肺炎(COVID-19)的KT受者,并随访至康复或死亡。在多变量分析中,年龄、肺炎以及在COVID-19感染前≤6个月进行的KT是死亡的预测因素,而胃肠道症状具有保护作用。生存分析显示,根据受者年龄和KT后的时间,四个亚组的死亡风险显著增加(年龄<65岁且移植后时间>6个月、年龄<65岁且时间≤6个月、年龄≥65岁且时间>6个月以及年龄≥65岁且时间≤6个月):死亡率分别为11.3%、24.5%、35.4%和54.5%(p<0.001)。与第一波(3月至6月)相比,第二波(7月至12月)的患者明显更年轻,肺炎发病率更低,接受特异性抗COVID-19治疗的频率也更低。第二波的总体死亡率较低(15.1%对27.4%,p<0.001),但危重症患者的死亡率相似(66.7%对58.1%,p=0.29)。在COVID-19大流行期间选择移植受者时,应考虑年龄与KT后时间之间的相互作用。高龄和近期进行KT手术应促使采取严格的保护措施,包括接种疫苗。

相似文献

7
COVID-19 in elderly kidney transplant recipients.老年肾移植受者中的 COVID-19 感染。
Am J Transplant. 2020 Oct;20(10):2883-2889. doi: 10.1111/ajt.16096. Epub 2020 Jul 6.

引用本文的文献

本文引用的文献

1
Position statement of the Spanish Society of Nephrology on the SARS-CoV-2 vaccines.西班牙肾脏病学会关于 SARS-CoV-2 疫苗的立场声明。
Nefrologia (Engl Ed). 2021 Jul-Aug;41(4):412-416. doi: 10.1016/j.nefroe.2021.09.001. Epub 2021 Sep 22.
4
COVID-19 in transplant recipients: The Spanish experience.器官移植受者中的 COVID-19:西班牙经验。
Am J Transplant. 2021 May;21(5):1825-1837. doi: 10.1111/ajt.16369. Epub 2020 Nov 10.
5
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.托珠单抗治疗 COVID-19 住院患者的疗效。
N Engl J Med. 2020 Dec 10;383(24):2333-2344. doi: 10.1056/NEJMoa2028836. Epub 2020 Oct 21.
7
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.羟氯喹治疗 COVID-19 住院患者的疗效。
N Engl J Med. 2020 Nov 19;383(21):2030-2040. doi: 10.1056/NEJMoa2022926. Epub 2020 Oct 8.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验